Digestery
Longevity supplements › Urolithin A and Muscle › Studies

Randomized trial · measured other health measures

4-month trial in middle-aged adults: muscle strength up 12%, peak power not clearly changed

Singh and colleagues · Cell reports. Medicine · 2022

Original title: Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Mixed

Muscle strength rose ∼12% with urolithin A. Peak power output, the main goal, did not clearly improve. Blood markers of poor mitochondrial efficiency and of inflammation fell, and muscle mitophagy proteins rose.

The study at a glance

Type of study
Randomized trial
Who or what was studied
Middle-aged adults
What was tested
Urolithin A (Mitopure) at two doses for 4 months, vs placebo
What it measured
Several kinds of outcomes
How long
17 weeks
Trial registration
NCT03464500
Who has a stake
Company stake
Authors are employees, board members or advisers of Amazentis SA, which makes Mitopure and sponsored the trial.
Journal
Cell reports. Medicine, 2022
Source
PubMed record 35584623. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • •The abstract does not say how many people took part.
  • •Lasted 17 weeks.
  • •Measured several kinds of outcomes.
  • –Company stake: Authors are employees, board members or advisers of Amazentis SA, which makes Mitopure and sponsored the trial.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: muscle strength and endurance

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    4

    3 mixed, 1 no difference

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    0

    None among the papers we read.

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    2

    2 benefit

  7. Cells in a dish

    1

    1 no direction

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does urolithin A improve muscle health with age?”

Unclear: small trials, mixed results.

Confidence: very low. Based on 9 on-topic papers.

Read the full answer

Of the other 3 papers on the same step: 2 mixed, 1 no difference. This one found mixed. It agrees with most of them.

  • Quoted in “What we found”: Four placebo-controlled trials in people tested urolithin A on muscle: two in middle-aged or older adults (one with 66 people) and two in trained male athletes (20 and 42).
  • Quoted in “What we found”: Three trials gave 1000 mg (1 g) a day; one compared two doses with placebo. Trials lasted from 4 weeks to 4 months.
  • Quoted in “What we found”: Three of the four trials had employees of Amazentis SA, maker of Mitopure, among their authors. Amazentis sponsored two of them.
  • Part of the finding “Strength rose in some tests, not others”.
  • Part of the finding “Trials in aging adults missed their main goals”.
  • Part of the finding “Markers moved, but energy output did not”.
  • Marked as a key paper in the research timeline: Middle-aged trial: strength up, main goal missed.
  • Open item for a person: Reviews Kuerec 2024 and Dao 2026 likely include trials Singh 2022 and Liu 2022; avoid counting the same trials twice.
  • Open item for a person: Singh 2022 abstract gives no sample size or doses; Dao 2026 mentions 500 mg and 1,000 mg arms of Singh et al.
  • Open item for a person: Singh 2022 and Liu 2022 missed primary goals but both reads set direction mixed; by the primary-outcome rule it may be none.

Other papers on the same step

See all 9 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 2 fields after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.